Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, provides isotope technology components for medical, scientific, and industrial use worldwide.
No risks detected for EUZ from our risk checks.
Flawless balance sheet with proven track record and pays a dividend.
Share Price & News
How has Eckert & Ziegler Strahlen- und Medizintechnik's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EUZ has not had significant price volatility in the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: EUZ exceeded the German Medical Equipment industry which returned 20.4% over the past year.
Return vs Market: EUZ exceeded the German Market which returned 3% over the past year.
Price Volatility Vs. Market
How volatile is Eckert & Ziegler Strahlen- und Medizintechnik's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall StShould You Use Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Statutory Earnings To Analyse It?
2 weeks ago | Simply Wall StHow Good Is Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ) At Creating Shareholder Value?
1 month ago | Simply Wall StShould You Buy Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ) For Its Upcoming Dividend In 3 Days?
Is Eckert & Ziegler Strahlen- und Medizintechnik undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: EUZ (€154.4) is trading above our estimate of fair value (€101.42)
Significantly Below Fair Value: EUZ is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: EUZ is good value based on its PE Ratio (37.4x) compared to the Medical Equipment industry average (53x).
PE vs Market: EUZ is poor value based on its PE Ratio (37.4x) compared to the German market (21.1x).
Price to Earnings Growth Ratio
PEG Ratio: EUZ is poor value based on its PEG Ratio (2.9x)
Price to Book Ratio
PB vs Industry: EUZ is overvalued based on its PB Ratio (5.5x) compared to the DE Medical Equipment industry average (4.5x).
How is Eckert & Ziegler Strahlen- und Medizintechnik forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EUZ's forecast earnings growth (13% per year) is above the savings rate (0.2%).
Earnings vs Market: EUZ's earnings (13% per year) are forecast to grow slower than the German market (22.4% per year).
High Growth Earnings: EUZ's earnings are forecast to grow, but not significantly.
Revenue vs Market: EUZ's revenue (7.2% per year) is forecast to grow faster than the German market (5.9% per year).
High Growth Revenue: EUZ's revenue (7.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EUZ's Return on Equity is forecast to be low in 3 years time (15.4%).
How has Eckert & Ziegler Strahlen- und Medizintechnik performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EUZ has high quality earnings.
Growing Profit Margin: EUZ's current net profit margins (11.8%) are higher than last year (11.1%).
Past Earnings Growth Analysis
Earnings Trend: EUZ's earnings have grown by 18.5% per year over the past 5 years.
Accelerating Growth: EUZ's earnings growth over the past year (8.2%) is below its 5-year average (18.5% per year).
Earnings vs Industry: EUZ earnings growth over the past year (8.2%) exceeded the Medical Equipment industry 8.2%.
Return on Equity
High ROE: EUZ's Return on Equity (15%) is considered low.
How is Eckert & Ziegler Strahlen- und Medizintechnik's financial position?
Financial Position Analysis
Short Term Liabilities: EUZ's short term assets (€148.5M) exceed its short term liabilities (€39.4M).
Long Term Liabilities: EUZ's short term assets (€148.5M) exceed its long term liabilities (€91.0M).
Debt to Equity History and Analysis
Debt Level: EUZ's debt to equity ratio (0.01%) is considered satisfactory.
Reducing Debt: EUZ's debt to equity ratio has reduced from 18.4% to 0.01% over the past 5 years.
Debt Coverage: EUZ's debt is well covered by operating cash flow (207383.3%).
Interest Coverage: EUZ's interest payments on its debt are well covered by EBIT (40.7x coverage).
What is Eckert & Ziegler Strahlen- und Medizintechnik current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: EUZ's dividend (1.1%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.26%).
High Dividend: EUZ's dividend (1.1%) is low compared to the top 25% of dividend payers in the German market (3.8%).
Stability and Growth of Payments
Stable Dividend: EUZ's dividends per share have been stable in the past 10 years.
Growing Dividend: EUZ's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (41.2%), EUZ's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: EUZ's dividends in 3 years are forecast to be well covered by earnings (33.3% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Andreas Eckert (60yo)
Dr. Andreas Eckert, PhD, is the Founder and Managing Partner of ELSA Eckert Life Science Accelerator GmbH. Dr. Exkert is the Founder of Eckert & Ziegler Strahlen & Medizintechnik AG and serves as its Chief ...
CEO Compensation Analysis
Compensation vs Market: Andreas's total compensation ($USD1.10M) is about average for companies of similar size in the German market ($USD1.43M).
Compensation vs Earnings: Andreas's compensation has increased by more than 20% in the past year.
|Chairman of Executive Board & CEO||no data||€976.52k||0.21% €1.6m|
|Head of Radiation Therapy Segment & Member of the Executive Board||3.5yrs||€365.95k||no data|
|Member of Executive Board||1.83yrs||€452.03k||no data|
|Head of Intragroup Services||8.5yrs||no data||no data|
|President of Eckert & Ziegler Isotope Products Inc.||no data||no data||no data|
|Vice President of Eckert & Ziegler Isotope Products Inc||no data||no data||no data|
|Managing Director of Eckert & Ziegler Cesio s.r.o.||6.5yrs||no data||no data|
Experienced Management: EUZ's management team is seasoned and experienced (5 years average tenure).
|Member of Supervisory Board||1.17yrs||€9.00k||no data|
|Chairman of Supervisory Board||7.17yrs||€40.00k||no data|
|Member of Supervisory Board||1.5yrs||€17.00k||no data|
|Deputy Chairman of the Supervisory Board||3yrs||€29.00k||no data|
|Member of Supervisory Board||3.17yrs||€16.00k||no data|
|Member of Supervisory Board||1.5yrs||€17.00k||no data|
Experienced Board: EUZ's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Eckert & Ziegler Strahlen- und Medizintechnik AG's company bio, employee growth, exchange listings and data sources
- Name: Eckert & Ziegler Strahlen- und Medizintechnik AG
- Ticker: EUZ
- Exchange: XTRA
- Founded: 1992
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €798.376m
- Shares outstanding: 5.15m
- Website: https://www.ezag.com
Number of Employees
- Eckert & Ziegler Strahlen- und Medizintechnik AG
- Robert-Rössle-Strasse 10
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EUZ||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||May 1999|
|EUZ||XTRA (XETRA Trading Platform)||Yes||Ordinary Shares||DE||EUR||May 1999|
|0NZY||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||May 1999|
|EUZd||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||EUR||May 1999|
|EUZ||ETLX (Eurotlx)||Yes||Ordinary Shares||IT||EUR||May 1999|
Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, provides isotope technology components for medical, scientific, and industrial use worldwide. It operates through three segments: Radiation Therapy, Radiopharma, and Isotope Products. The Radiation Therapy segment develops, manufactures, markets, and sells radioactive products for cancer therapy. This segment offers small radioactive implants for the treatment of prostate cancer seeds; and tumor radiation devices and eye applicators. This segment’s products and equipment are used by oncologists, radiotherapists, urologists, ophthalmologists, and medical physicists. The Radiopharma segment operates in the field of molecular imaging and nuclear medicine; and supplies various radiopharmaceuticals, radiochemicals, and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. This segment provides products in the categories of radiosynthesis technology, radiochromatography, and radionuclides. The Isotope Products segment offers sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration, and environmental monitoring sources and solutions; and bulk radioisotopes for pharmaceutical, therapeutic, and industrial product manufacturers. It also provides custom and one-off design and manufacturing services. In addition, the company offers services for collection, recycling, and disposal of sealed radioactive sources and low activity isotope related waste from hospitals, research institutes, and industries. Eckert & Ziegler Strahlen- und Medizintechnik AG was founded in 1992 and is headquartered in Berlin, Germany.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/07 20:53|
|End of Day Share Price||2020/07/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.